Results 81 to 90 of about 1,964,998 (260)

RNA Sequencing Resolves Cryptic Pathogenic Variants in Mitochondrial Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Mitochondrial diseases are the most common inherited metabolic disorders, characterized by pronounced clinical and genetic heterogeneity that complicates molecular diagnosis. Although DNA‐based sequencing approaches have become standard in genetic testing, up to half of patients remain without a definitive diagnosis.
Zhimei Liu   +21 more
wiley   +1 more source

Evaluation of the reproducibility of amplicon sequencing with Illumina MiSeq platform

open access: yesPLOS ONE, 2017
Illumina's MiSeq has become the dominant platform for gene amplicon sequencing in microbial ecology studies; however, various technical concerns, such as reproducibility, still exist. To assess reproducibility, 16S rRNA gene amplicons from 18 soil samples of a reciprocal transplantation experiment were sequenced on an Illumina MiSeq.
Chongqing Wen   +10 more
openaire   +6 more sources

Summary of the sequence assembly after Illumina sequencing in red perilla.

open access: yes, 2015
Summary of the sequence assembly after Illumina sequencing in red perilla.
Kazuki Saito (86281)   +4 more
core   +1 more source

WebCARMA: a web application for the functional and taxonomic classification of unassembled metagenomic reads [PDF]

open access: yes, 2009
Gerlach W, Jünemann S, Tille F, Goesmann A, Stoye J. WebCARMA: a web application for the functional and taxonomic classification of unassembled metagenomic reads. BMC Bioinformatics.
Jünemann, Sebastian   +14 more
core   +1 more source

Sertraline Treatment Can Mimic Niemann‐Pick Type C Biomarker Profile: A Diagnostic Pitfall

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Oxysterols (cholestane‐3β,5α,6β‐triol and 7‐ketocholesterol) and N‐palmitoyl‐O‐phosphocholineserine (PPCS) are sensitive biomarkers for Niemann‐Pick disease type C (NPC) screening. However, false‐positive results occur, with a biomarker profile suggestive of NPC despite the absence of pathogenic variants in genes involved in NPC or ...
Maria Makrygianni   +19 more
wiley   +1 more source

Uncovering G Protein‐Coupled Receptors: Novel Targets and Biomarkers for Predicting Glioma Prognosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Low‐grade gliomas (LGG) exhibit significant heterogeneity and recurrence risk. G protein‐coupled receptors (GPCR) contribute to glioma malignant progression, but their prognostic value remains unclear. This work attempts to formulate a GPCR‐based outcome‐predicting model for LGG. Methods Based on TCGA LGG data, the enrichment scores
Jun Yang   +4 more
wiley   +1 more source

Illumina GAII DNA sequence analysis of eight genotypes and mixed DNA.

open access: yes, 2013
Illumina GAII DNA sequence analysis of eight genotypes and mixed DNA.
Qijian Song (277210)   +6 more
core   +1 more source

Bi‐ and Mono‐Allelic RFC1 Expansion in a North American Cohort With Idiopathic Axonal Neuropathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective RFC1 biallelic repeat expansion is increasingly recognized as a cause of chronic idiopathic axonal polyneuropathy (CIAP), but it remains challenging to know who to test. This study aims to determine the prevalence of biallelic and monoallelic RFC1 expansions and their corresponding neuropathy phenotypes in CIAP patients and identify ...
Amro M. Stino   +25 more
wiley   +1 more source

Barcode Sequencing by Illumina NGS v1

open access: yes
This protocol details the extraction of genomic DNA from cells and barcode sequencing by NGS.
Nicholas A. Popp   +4 more
openaire   +1 more source

Number of sequence reads extracted from intensity files using Illumina and Rolexa analysis.

open access: yes, 2013
Number of sequence reads extracted from intensity files using Illumina and Rolexa analysis.
Andrew J. Sharp (141304)   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy